Alkem Laboratories Ltd
Pharmaceuticals & Biotechnology | Mid Cap
Alkem Laboratories demonstrates a strong financial position, particularly in solvency, growth, and profitability. The company maintains a healthy balance sheet with low debt levels and robust equity. Revenue and earnings growth are impressive, indicating effective management and market positioning. Profitability metrics, such as ROCE, ROE, and ROA, consistently reflect efficient capital utilization. However, there are some areas of concern, notably in efficiency and liquidity. The company's turnover ratios for fixed assets, inventory, and capital are low, suggesting potential inefficiencies in asset utilization. While the company exhibits high liquidity, its cash flow management needs improvement. Capital expenditure is a key area needing attention, as it impacts overall financial health. Despite these challenges, Alkem's strong performance in core areas positions it well for future growth and stability within the healthcare industry.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio10.00
- Financial Ratio8.40
- Profitability Ratio10.00
- Efficiency Ratio3.67
- Coverage Ratio9.20
- Solvency Ratio10.00
- Liquidity Ratio7.46
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBullish
- 2 HoursStrong Bullish
- 4 HoursBullish
- 1 DayNeutral
- 1 WeekBearish
- 1 MonthBullish
Alkem Laboratories demonstrates a strong financial position, particularly in solvency, growth, and profitability. The company maintains a healthy balance sheet with low debt levels and robust equity. Revenue and earnings growth are impressive, indicating effective management and market positioning. Profitability metrics, such as ROCE, ROE, and ROA, consistently reflect efficient capital utilization. However, there are some areas of concern, notably in efficiency and liquidity. The company's turnover ratios for fixed assets, inventory, and capital are low, suggesting potential inefficiencies in asset utilization. While the company exhibits high liquidity, its cash flow management needs improvement. Capital expenditure is a key area needing attention, as it impacts overall financial health. Despite these challenges, Alkem's strong performance in core areas positions it well for future growth and stability within the healthcare industry.
Overall Valuation Score
P/E RATIO (TTM)
29.40
Industry Median
28.62
Mid Cap Median
36.34
P/E RATIO
27.91
P/B RATIO
4.65
Industry Median
3.17
Mid Cap Median
7.64
P/S RATIO
4.41
Industry Median
3.42
Mid Cap Median
6.30
Others
PEG RATIO
3.60
EV/EBITDA RATIO
18.77
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹5373.5 as on Jun 19, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Alkem Laboratories demonstrates outstanding growth across all key metrics. Revenue, operating profit, EPS, assets, and net income are all growing at high rates. This reflects strong market positioning, effective management strategies, and a robust ability to capitalize on opportunities. The company's consistent growth underscores its financial health and potential for future success.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 19.95 | 9.07 | 9.22 | 2.34 | 13.47 |
| Operating Profit Growth Rate | 5.6 | -21.03 | 38.66 | 11.69 | 19.63 |
| Earnings Per Share (EPS) Growth | 3.82 | -40.19 | 82.47 | 20.59 | 6.29 |
| Asset Growth Rate | 22.14 | -2.22 | 13.22 | 13.59 | 17.99 |
| Net Income Growth Rate | 3.83 | -40.06 | 79.84 | 22.31 | 6.14 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Alkem Laboratories demonstrates a strong financial performance with high adjusted EPS, cash EPS, and book value per share. The company's dividend per share is also robust, reflecting its commitment to returning value to shareholders. However, the high capital expenditures indicate significant investments, which need to be carefully managed to ensure they yield positive returns. Overall, the company exhibits solid financial health with areas needing focused attention.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 143.75 | 93.25 | 160.5 | 188.42 | 211.42 |
| Cash Earnings Per Share (Cash EPS) | 165.33 | 109.75 | 175.83 | 214.33 | 227.75 |
| Book Value Per Share | 719.83 | 753.75 | 859.33 | 998.75 | 1151.67 |
| Dividend Per Share (DPS) | 34.41 | 50.21 | 40.55 | 45.28 | 53.9 |
| Capital Expenditures (CapEx) | 328 | 230 | 187 | 635 | 487 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
Alkem Laboratories exhibits outstanding profitability across all key metrics. High gross profit margins, ROCE, ROE, ROA, operating margins, and net margins demonstrate efficient operations and strong financial performance. The company effectively manages its costs and generates substantial profits from its revenue. This robust profitability underscores the company's financial health and competitive advantage.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 16.46 | 11.31 | 15.39 | 16.62 | 17.83 |
| Return on Capital Employed (ROCE) | 18 | 14 | 20 | 20 | 21 |
| Return on Equity (ROE) | 19.45 | 11.13 | 17.56 | 18.48 | 17.01 |
| Return on Assets (ROA) | 14.6 | 11.79 | 14.44 | 14.2 | 14.4 |
| Operating Margin | 19.32 | 13.98 | 17.75 | 19.38 | 20.43 |
| Net Margin | 15.8 | 8.68 | 14.3 | 17.08 | 15.98 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
Alkem Laboratories faces significant challenges in its efficiency. All turnover ratios are low, suggesting potential issues with asset utilization and operational processes. The company needs to improve how it uses its assets to generate revenue. The extended days sales in inventory and receivable days indicate slow inventory turnover and collections, which could tie up working capital and affect cash flow. Boosting operational efficiency will be crucial for enhancing overall performance.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 3.66 | 4.32 | 4.41 | 4.55 | 3.66 |
| Inventory Turnover Ratio | 3.34 | 3.66 | 4.07 | 3.87 | 3.87 |
| Receivables Turnover Ratio | 6.09 | 5.77 | 5.78 | 5.49 | 5.4 |
| Days Sales in Inventory Ratio | 109.28 | 99.73 | 89.68 | 94.32 | 94.32 |
| Receivable Days | 59.93 | 63.26 | 63.15 | 66.48 | 67.59 |
| Capital Turnover Ratio | 1.22 | 1.27 | 1.2 | 1.03 | 1 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
Alkem Laboratories exhibits strong coverage ratios, indicating a robust ability to meet its interest and dividend obligations. The company comfortably covers its interest expenses with its earnings, and its equity dividend coverage is also solid. This reflects prudent financial management and a low risk of financial distress. The company's financial stability is enhanced by its ability to service its debts and dividends effectively.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 36.46 | 13.2 | 19.06 | 21.71 | 18.83 |
| Equity Dividend Coverage Ratio | 4 | 1.64 | 3.7 | 4 | 3.57 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
Alkem Laboratories exhibits excellent solvency, indicating a strong and stable financial structure. The company maintains very low levels of debt relative to equity and assets, reflecting a conservative approach to financial leverage. This strong equity base provides a solid foundation for future growth and resilience against economic downturns. The company's financial risk is minimized due to its robust solvency position, enhancing its long-term sustainability.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.01 | 0.01 | 0.02 | 0.05 | 0.06 |
| Debt to Equity Ratio | 0.01 | 0.01 | 0.02 | 0.05 | 0.06 |
| Equity Ratio | 0.99 | 0.99 | 0.98 | 0.95 | 0.94 |
| Debt To Asset Ratio | 0.01 | 0.01 | 0.02 | 0.04 | 0.04 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
Alkem Laboratories demonstrates a mixed liquidity profile. While the quick ratio indicates a strong ability to meet short-term obligations with highly liquid assets, the current ratio suggests there is room for improvement in managing current assets and liabilities. The cash ratio, being average, points to moderate cash reserves. The operating cash flow ratio is weak, indicating challenges in generating sufficient cash from operations to cover current liabilities. Overall, the company maintains high liquidity but optimizing cash flow from its operations will be beneficial.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.96 | 2.19 | 2.4 | 2.45 | 2.42 |
| Quick Ratio | 1.4 | 1.63 | 1.87 | 1.88 | 1.88 |
| Cash Ratio | 0.48 | 0.57 | 0.31 | 0.31 | 0.28 |
| Operating Cash Flow Ratio | 0.21 | 0.36 | 0.39 | 0.38 | 0.32 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Abbott India Ltd | 8.68 | 35.89 | Neutral | 1892.00 | 730.39 | 1552.00 |
| 2 | Glaxosmithkline Pharmaceuticals Ltd | 8.38 | 38.14 | Neutral | 1309.00 | 59.73 | 1036.00 |
| 3 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 49.64 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 4 | Alkem Laboratories Ltd | 8.08 | 27.91 | Neutral | 3005.00 | 182.76 | 2351.00 |
| 5 | Gland Pharma Ltd | 7.91 | 35.27 | Overvalued | 1630.00 | 78.88 | 1027.00 |
| 6 | Lupin Ltd | 7.84 | 20.16 | Neutral | 8816.00 | 139.25 | 5355.00 |
| 7 | Ajanta Pharma Ltd | 7.72 | 36.27 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 8 | Mankind Pharma Ltd | 7.61 | 52.10 | Highly Overvalued | 3617.00 | 49.34 | 1938.00 |
| 9 | Zydus Lifesciences Ltd | 7.60 | 21.38 | Neutral | 8475.00 | 35.38 | 5124.00 |
| 10 | Laurus Labs Ltd | 7.10 | 85.84 | Neutral | 1778.00 | 13.72 | 890.00 |
| 11 | Dr Reddys Laboratories Ltd | 6.49 | 25.31 | Neutral | 6454.00 | 38.58 | 4158.00 |
| 12 | Glenmark Pharmaceuticals Ltd | 6.36 | 45.87 | Neutral | 4572.00 | -7.12 | 1362.00 |
| 13 | Ipca Laboratories Ltd | 6.33 | 35.26 | Neutral | 1979.00 | 44.64 | 1184.00 |
Alkem Laboratories demonstrates mixed management effectiveness. The company exhibits strong profit growth and consistent dividend payouts, which are positive indicators. However, there are concerns regarding declining sales growth and increasing working capital days. While ROCE is healthy, the decrease in promoter holding is also a point of concern. Overall, the management's effectiveness is rated as mixed, requiring attention to sales and operational efficiency to ensure sustainable growth and profitability.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Strong Profit Growth | 14% (5Y) | Profit growth is strong over the long term |
| Consistent Dividend Payout | 25% (Mar 2025) | Company consistently shares profits with shareholders | |
| CONS | Declining Sales Growth | 2.34% (Mar 2025) | Sales growth has slowed down recently |
| Increasing Working Capital Days | 172 (Mar 2025) | Working capital management shows signs of inefficiency |
Financial Performance & Growth
Alkem Laboratories exhibits mixed performance in financial performance and growth. While profitability metrics are generally strong, sales growth has slowed down recently. The compounded sales growth shows a moderate expansion over the years, but the latest figures indicate a deceleration. The compounded profit growth, on the other hand, remains robust, suggesting effective cost management or other income contributions. However, the inconsistency in annual sales and profit figures indicates some volatility in financial performance.
| Metric | 2014–2016 | 2017–2019 | 2020–2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Compounded Sales Growth (%) | 25.6% | 14.5% | 15.3% | 9.08% | 9.21% | 2.34% |
| Compounded Profit Growth (%) | 28.6% | -0.07% | 24.6% | -39.0% | 79.2% | 22.3% |
Capital Efficiency & Returns
Alkem Laboratories demonstrates reasonable capital efficiency and returns. The Return on Capital Employed (ROCE) is healthy, indicating effective utilization of capital. However, there has been some fluctuation in ROCE over the years. The cash conversion cycle has increased, suggesting potential inefficiencies in managing working capital.
| Metric | 2014–2016 | 2017–2019 | 2020–2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROCE (%) | 16.3% | 18% | 20.7% | 14% | 20% | 20% |
Financial Health & Prudence
Alkem Laboratories exhibits an average financial health and prudence level. The debt management indicates that leverage is somewhat under control, but borrowings have fluctuated.
| Metric | 2014–2016 | 2017–2019 | 2020–2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Borrowings (Cr) | 1030.6 | 867 | 2309.3 | 1397 | 1418 | 1381 |
Shareholding & Ownership Structure
The shareholding and ownership structure of Alkem Laboratories reveals some shifts. The promoter holding has decreased over the years. Institutional holding, including FII and DII, indicates the attractiveness of the company to institutional investors.
| Metric | Mar 2017 | Mar 2019 | Mar 2021 | Mar 2023 | Mar 2025 |
|---|---|---|---|---|---|
| Promoter Holding (%) | 66.97% | 66.02% | 60.16% | 57.16% | 55.13% |
| FII Holding (%) | 4.22% | 2.44% | 4.42% | 4.44% | 9.40% |
| DII Holding (%) | 2.53% | 5.11% | 13.20% | 16.69% | 19.42% |
Alkem Laboratories faces a moderate risk profile. An increase in working capital days points to potential operational inefficiencies. A decreasing promoter holding and increasing competition, as indicated by peer comparison, are also concerning. However, the company maintains a reasonable debt level and interest coverage. Given these factors, the overall risk is assessed as moderate, requiring careful monitoring of working capital management and competitive dynamics.
Segment performance volatility
The quarterly results reveal fluctuations in sales and profit growth, indicating some level of segment performance volatility.
Foreign exchange or interest rate exposure
The presence of borrowings and interest expenses indicates some exposure to interest rate fluctuations. Additionally, given that Alkem Laboratories operates in the healthcare sector with international operations, there is likely some level of foreign exchange exposure.
Regulatory compliance cost trends
As a pharmaceutical company, Alkem Laboratories is subject to various regulatory requirements and compliance standards. The costs associated with regulatory compliance can impact profitability and operational efficiency.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 105367.45Bullish
- SMA 205357.82Bullish
- SMA 505339.70Bullish
- EMA 105366.81Bullish
- EMA 205359.79Bullish
- EMA 505348.85Bullish
- DEMA 105374.46Bullish
- DEMA 205371.03Bullish
- DEMA 505356.19Bullish
- TEMA 105376.20Bullish
- TEMA 205374.28Bullish
- TEMA 505372.66Bullish
- MACD8.64Bullish
- ADX12.65Weak Trend
- IndicatorValueSignal
- RSI58.52Neutral
- CCI135.24Overbought
- ROC 90.67Bullish
- ROC 140.77Bullish
- ROC 250.63Bullish
- Stoch K61.71Neutral
- Stoch D53.11Neutral
- IndicatorValueSignal
- BB Upper5385.82Neutral
- BB Middle5357.82Neutral
- BB Lower5329.83Neutral
- ATR29.41Low Volatility
- IndicatorValueSignal
- MFI55.30Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 105361.25Bullish
- SMA 205350.75Bullish
- SMA 505328.65Bullish
- EMA 105363.87Bullish
- EMA 205353.16Bullish
- EMA 505349.00Bullish
- DEMA 105376.26Bullish
- DEMA 205368.22Bullish
- DEMA 505333.65Bullish
- TEMA 105379.04Bullish
- TEMA 205377.77Bullish
- TEMA 505352.88Bullish
- MACD11.92Bullish
- ADX32.46Strong Trend
- IndicatorValueSignal
- RSI57.63Neutral
- CCI155.10Overbought
- ROC 90.60Bullish
- ROC 140.73Bullish
- ROC 251.43Bullish
- Stoch K61.83Neutral
- Stoch D66.80Neutral
- IndicatorValueSignal
- BB Upper5384.21Neutral
- BB Middle5350.75Neutral
- BB Lower5317.29Neutral
- ATR38.73Low Volatility
- IndicatorValueSignal
- MFI68.71Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 105349.95Bullish
- SMA 205340.20Bullish
- SMA 505375.36Bullish
- EMA 105351.32Bullish
- EMA 205345.33Bullish
- EMA 505367.99Bullish
- DEMA 105365.54Bullish
- DEMA 205341.31Bullish
- DEMA 505334.42Bullish
- TEMA 105374.37Bullish
- TEMA 205363.01Bullish
- TEMA 50N/AN/A
- MACD0.25Bullish
- ADX23.44Weak Trend
- IndicatorValueSignal
- RSI54.58Neutral
- CCI90.28Neutral
- ROC 90.95Bullish
- ROC 141.79Bullish
- ROC 252.58Bullish
- Stoch K67.63Neutral
- Stoch D54.38Neutral
- IndicatorValueSignal
- BB Upper5393.47Neutral
- BB Middle5340.20Neutral
- BB Lower5286.93Neutral
- ATR67.92Low Volatility
- IndicatorValueSignal
- MFI66.00Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 105326.40Bullish
- SMA 205350.20Bullish
- SMA 505420.89Bearish
- SMA 1005470.61Bearish
- SMA 2005519.44Bearish
- EMA 105339.85Bullish
- EMA 205356.78Bullish
- EMA 505401.94Bearish
- EMA 1005441.87Bearish
- EMA 2005432.82Bearish
- DEMA 105335.12Bullish
- DEMA 205318.90Bullish
- DEMA 505342.81Bullish
- DEMA 1005405.00Bearish
- DEMA 2005503.08Bearish
- TEMA 105356.15Bullish
- TEMA 205313.65Bullish
- TEMA 505326.61Bullish
- TEMA 1005330.07Bullish
- TEMA 2005440.49Bearish
- MACD-26.24Bullish
- ADX16.27Weak Trend
- IndicatorValueSignal
- RSI50.21Neutral
- CCI-2.16Neutral
- ROC 14-2.29Bearish
- ROC 25-1.66Bearish
- Stoch K42.13Neutral
- Stoch D32.39Neutral
- IndicatorValueSignal
- BB Upper5494.75Neutral
- BB Middle5350.20Neutral
- BB Lower5205.65Neutral
- ATR125.20Low Volatility
- IndicatorValueSignal
- MFI48.31Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 205430.45Bearish
- SMA 505429.79Bearish
- EMA 205429.79Bearish
- EMA 505405.16Bearish
- DEMA 205395.03Bearish
- DEMA 505511.98Bearish
- TEMA 205335.75Bearish
- TEMA 505440.82Bearish
- MACD-31.29Bearish
- ADX14.76Weak Trend
- IndicatorValueSignal
- RSI47.53Neutral
- CCI-41.94Neutral
- ROC 14-4.20Bearish
- ROC 25-4.64Bearish
- Stoch K38.40Neutral
- Stoch D44.51Neutral
- IndicatorValueSignal
- BB Upper5696.92Neutral
- BB Middle5430.45Neutral
- BB Lower5163.98Neutral
- ATR306.67Low Volatility
- IndicatorValueSignal
- MFI52.49Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 65503.42Bearish
- SMA 125409.22Bullish
- SMA 245387.32Bullish
- EMA 65465.48Bullish
- EMA 125415.47Bullish
- EMA 245220.28Bullish
- DEMA 65485.22Bullish
- DEMA 125540.23Bearish
- DEMA 245679.24Bearish
- TEMA 65452.63Bullish
- TEMA 125484.63Bullish
- TEMA 245578.21Bearish
- MACD616.31Bearish
- ADX27.73Strong Trend
- IndicatorValueSignal
- RSI58.82Neutral
- CCI72.36Neutral
- ROC 2513.76Bullish
- ROC 5051.85Bullish
- Stoch K52.71Neutral
- Stoch D60.32Neutral
- IndicatorValueSignal
- BB Upper5958.33Neutral
- BB Middle5338.58Neutral
- BB Lower4718.83Neutral
- ATR534.46Low Volatility
- IndicatorValueSignal
- MFI71.94Neutral